Plaque Psoriasis Market by Treatment, by Route of Administration, by End-user, and by Region

The global plaque psoriasis market accounted for USD 19.87 billion in 2023 and is expected to reach USD 56.80 billion by 2034 with a CAGR of 10.02% during the forecast period 2024-2034. The market will grow due to factors such as the rising prevalence of plaque psoriasis, improvements in treatment options, rising awareness and diagnosis rates, technological advancements in healthcare, and rising investments in R&D.

The global increase in the prevalence of plaque psoriasis is a major factor propelling the market's expansion. The number of people seeking therapy is rising due to a variety of factors, including lifestyle modifications, environmental triggers, genetic predisposition, and improved diagnosis. The effectiveness and safety of treatments for plaque psoriasis are improved by technological developments in medication delivery, diagnosis, and therapy methods. Better treatment outcomes and patient experiences are provided by cutting-edge technologies such as wearable sensors, phototherapy equipment, and biologics, which propel market expansion. For instance, AbbVie reported encouraging findings from a Phase 3 trial assessing their experimental treatment for moderate to severe plaque psoriasis in January 2024.

By Treatment, the biologic therapies segment accounted for the highest revenue-grossing segment in the global plaque psoriasis market in 2023 and is predicted to grow at the fastest CAGR during the forecast period owing to the superior efficacy, targeted action, and increasing adoption among physicians and patients seeking advanced treatment options for severe plaque psoriasis. For instance, Janssen, the pharmaceutical division of Johnson & Johnson, reported encouraging Phase 3 trial findings for their experimental interleukin-23 inhibitor for moderate-to-severe plaque psoriasis in December 2023.

By Route of Administration, the injectable segment accounted for the highest revenue-grossing segment in the global plaque psoriasis market in 2023 owing to the convenience of administration, sustained therapeutic effect, and preference among patients and healthcare providers for effective management of moderate to severe plaque psoriasis. For instance, in December 2023, the FDA approved a new use for one of Amgen's biologic treatments; treating pediatric patients' plaque psoriasis. Additionally, the oral segment is predicted to grow at the fastest CAGR during the forecast period owing to the convenience, patient preference for oral administration, and advancements in oral treatment options offering improved efficacy and safety profiles for managing plaque psoriasis.

By End-User, the hospital's segment accounted for the highest revenue-grossing segment in the global plaque psoriasis market in 2023 owing to the availability of specialized medical expertise, advanced treatment modalities, and comprehensive care facilities, making hospitals the preferred choice for managing severe cases of plaque psoriasis requiring intensive medical intervention. For instance, Johnson & Johnson introduced a new digital health platform in February 2024 with the goal of helping people with plaque psoriasis by offering tools and support. Additionally, the homecare segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on patient-centered care, technological advancements enabling home-based treatments, and preference for convenience and comfort among patients seeking management of plaque psoriasis in a familiar environment.

North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of plaque psoriasis, well-established healthcare infrastructure, favorable reimbursement policies, and extensive research and development activities driving innovation in treatment options within the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to increasing awareness, rising healthcare expenditure, expanding access to advanced treatment options, and a growing patient pool seeking effective management of plaque psoriasis across diverse demographics. For instance, in November 2023, Eli Lilly and Company reported favorable top-line outcomes from a Phase 3 study assessing a possible novel treatment for plaque psoriasis.

This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.

Report Scope:

• Base Year: 2023
• Forecast Period: 2024-2034
• Study Coverage
• Market Forecast by Treatment, Route of Administration, and End-User
• Market Forecast for 5 Regions and 17+ Countries
• North America (U.S. and Canada)
• Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
• Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
• Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
• MEA (South Africa, GCC, Rest of MEA)
• Exhaustive Company Profiles of the Top 10+ Major Market Players
• 20% Free Customization Available to Meet Your Exact Requirement

Segmentation: Plaque Psoriasis Market Report 2023 - 2034

Plaque Psoriasis Market Analysis & Forecast by Treatment 2023 - 2034 (Revenue USD Bn)

• Topical Therapy
• Phototherapy
• Systemic Agents
• Biologic therapies
• Others

Plaque Psoriasis Market Analysis & Forecast by Route of Administration 2023 - 2034 (Revenue USD Bn)

• Oral
• Injectable

Plaque Psoriasis Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)

• Hospitals
• Homecare
• Speciality Centers
• Others

Plaque Psoriasis Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• UK
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of LATAM
• Middle East & Africa
• South Africa
• GCC
• Rest of MEA